Literature DB >> 27127139

Adenocarcinoma of the Oesophagus and Oesophagogastric Junction: Analysis of Incidence and Risk Factors.

Tuomo Rantanen1, Niku Oksala2, Juhani Sand3.   

Abstract

BACKGROUND/AIM: Conflicting data exist on the changes in the incidence of oesophageal (EAC) and oesophagogastric junction adenocarcinoma (EGJAC). In addition, risk factors of the disease are only partly known. The aim of the study was to evaluate the incidence of EAC and EGJAC in Finland as well as risk factors of these cancers. PATIENTS AND METHODS: The complete number of new EAC and EGJAC cases between January 1980 and December 2007 in Finland was provided by the Finnish Cancer Registry. All treated EAC and EGJAC patients in the Pirkanmaa Hospital District between January 1980 and December 2007 were included in the study.
RESULTS: The incidence of EAC increased significantly in Finland. Barrett's oesophagus (BE) was associated with the risk of EAC and cholecystectomy with the risk of EGJAC.
CONCLUSION: A significant increase in EAC was found in Finland over the course of nearly 30 years, indicating that the increase in EAC in Finland is existent in the long term. BE was associated with the risk of EAC and cholecystectomy with the risk of EGJAC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Finland; Oesophageal adenocarcinoma; epidemiology; incidence; oesophagogastric junction adenocarcinoma; risk factors

Mesh:

Year:  2016        PMID: 27127139

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.

Authors:  Mimi C Tan; Nabil Mansour; Donna L White; Amy Sisson; Hashem B El-Serag; Aaron P Thrift
Journal:  Aliment Pharmacol Ther       Date:  2020-05-26       Impact factor: 8.171

2.  Improvement of atropine on esophagogastric junction observation during sedative esophagogastroduodenoscopy.

Authors:  Zhihao Chen; Lingang Liu; Jiangfeng Tu; Guangming Qin; Weiwei Su; Xiaoge Geng; Xiaojun Chen; Hongguang Wu; Wensheng Pan
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

3.  Clinical significance of post-operative bile reflux gastritis.

Authors:  Khek Yu Ho
Journal:  JGH Open       Date:  2022-03-22

4.  Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma.

Authors:  Yin-Qiao Liu; Ling-Yu Chu; Tian Yang; Biao Zhang; Zheng-Tan Zheng; Jian-Jun Xie; Yi-Wei Xu; Wang-Kai Fang
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.840

5.  Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction.

Authors:  Ming-Zhi Cai; Chen-Bin Lv; Li-Sheng Cai; Qiu-Xian Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.